<!–View this article in .txt format–>
HONG KONG, CHINA
– EQS Newswire – 15
May 2020 – A fully integrated biopharmaceutical company — Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”; Stock code: 0690.HK) is
pleased to announce that its wholly-owned subsidiary Shenzhen Watsin Genetech
Limited (Watsin) reached a partnership with Chengdu Medlinker Technology
Company Limited (Medlink), to further develop digital marketing channels for the
Group’s products, and to expand industry value chain downstream to pharmaceutical
E-commerce. According to the agreement, both companies will start working on
Genetime®, expanding its marketing channel to dermatology related clinical experts,
and will collaborate across several verticals,
including smart healthcare, disease management, patient and clinical
practitioner education, academic marketing, healthcare big data, and drug
tracing system, to create an integrated healthcare offering.
The win-win
collaboration between the Group and Medlink will allow both companies to leverage
their advantages in drug development and pharmaceutical e-commerce sector,
respectively; the Group has a deep product pipeline, breadth of experience in
working with clinical practitioners, and rich clinical resources across many
therapeutic areas, while Medlink has a powerful online healthcare management system, online healthcare
consultation service, e-prescription, system allowing medical insurance
payment, integrated service of online prescription and drug delivery, and
highly efficient disease management system. By connecting clinical practitioners
and patient with information technology, we can effectively integrate online
and offline academic marketing, educate clinical practitioners and patients
more easily, and satisfy patient’s demand via drug delivery to their doorstep;
the collaboration also allows real-time therapy progress tracking, enhancing
both treatment and compliance rate, and timely adjustment of treatment plan,
increasing drug effectiveness. As a result, the collaboration enhance product
reachability, take better care of more patients, ultimately driving up clinical
and market value of the product.
GeneTime®, a
prescription drug for wound and ulcer healing, is the star product of the Group
and has been chosen to be the first product for the collaboration. GeneTime® has
clear and broad indications, promising a potential massive market. In recent
years, the Group placed heavy importance on further developing the market of GeneTime®;
in 2019 GeneTime® reached 125 million HKD of sales, a 72.8% growth YoY. In
order to further develop GeneTime®’s competitiveness, the Group also started two
new R&D projects for the product in November 2019, which is expected to
expand GeneTime®’s applications. The collaboration with Medlink is also another
important enhancement initiative for GeneTime®. Especially within the period of
COVID-19, patients have changed their perception towards pharmaceutical
e-commerce, over 10% increase is seen in PRC pharmaceutical e-commerce sales in
1Q2020. In addition, the collaboration is very well-timed as it takes advantage
of the upcoming dermatological disease “high season” during the summer. In
addition to GeneTime®, the Company plans to place other products, including
nearly launched
chronic disease products Uni-PTH and Uni-E4, into the collaboration scope; the
collaboration develops solid base for fast future product launches.
Referring to the
collaboration, Mr. Kingsley Leung, the Chairman of Uni-Bio Science Group said, “The collaboration with Medlink is an important milestone of the Group’s
commercial development. During the period of COVID-19, there has been an
increased demand for online hospitals and pharmacies. In the long term, the
collaboration adheres to the national policy of encouraging “healthcare + internet”.
In the backdrop of both changing patient behaviors and drug distribution trends,
the Group has to take proactive steps to pioneer new business models to take
advantage of these changes. Our expansion into online healthcare will deliver
much better service for patient and clinical practitioner, expand our available
marketing channels,
and enhance brand awareness. We expect the collaboration will become a strong
future driver of GeneTime® sales and learning from this exercise can easily be
replicated to other products, to develop greater sales growth for all products
in the future.”
